Pharmacy Website
    Clinic Website

    Intelligence » Melanoma » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain

    Thursday, September 20, 2018 -- Results from a clinical trial show that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) halted the growth of or shrank metastatic brain tumors in more than half of participants with melanoma that had spread to the brain.

    Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

    Tuesday, September 18, 2018 -- Proactive adjuvant treatment could extend melanoma patient lives

    Novartis melanoma combination wins key thumbs-up from cost watchdog NICE after Opdivo shut out

    Tuesday, September 18, 2018 -- The National Institute for Health and Care Excellence (NICE) has given its blessing to the combination of Novartis’ Tafinlar and Mekinist in patients with stage III BRAF V600 mutation-positive melanoma after surgery. The decision comes just one week after Bristol-Myers Squibb failed to gain a recommendation for coverage in the U.K. for Opdivo in the same setting.